Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  CardiovascularMedicationType 2 DiabetesIssue 640

Death Risk Drops by 50% for Diabetes Patients Using Statins

Type 2 diabetes patients on statin drugs have lower mortality risk....

Advertisement

In randomized clinical trials, involving 5,152 men and women from 66 to 96 years of age statin medications have been shown to reduce the risk of death in people with type 2 diabetes.

Vilmundur Gudnason, MD, PhD, of the University of Iceland, and colleagues wanted to see if statins had the same beneficial effect in observational studies on older people with type 2 diabetes.

They found that type 2 diabetes patients taking statin drugs had a 50 percent lower risk of dying from heart-related causes and a 53 percent lower risk of dying from all causes, compared to those not taking statins.

Among those without diabetes, statin use was associated with 16 percent lower risk of heart-related death and a 30 percent lower risk of death from all causes.

Diabetes patients who used statins had a similar risk of death as the general population without diabetes. In other words, statin use lowered the risk of death to normal levels, rather than the increased risk generally associated with diabetes.

According to the authors, this observational study adds to a body of evidence showing that statin use may be beneficial for people with type 2 diabetes.

The results urgently call for other population-based studies with comparable information to confirm the effect of statin use on death risk in individuals with type 2 diabetes.

BMJ Open August 2012

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 23 August, 2012 and appeared in  CardiovascularMedicationType 2 DiabetesIssue 640

Past five issues: Diabetes Clinical Mastery Series Issue 247 | Issue 787 | Diabetes Clinical Mastery Series Issue 246 | SGLT-2 Inhibitors Special Edition June 2015 | Issue 786 |

2015 Most Popular Articles:

Triple Therapy Improves Glycemia in Type 1 Diabetes
Posted June 19, 2015
A Dual SGLT1/SGLT2 Inhibitor Can be a Treatment Option in Type 1 Diabetics
Posted June 12, 2015
Canagliflozin and Its Effects on Weight Loss and BP
Posted June 12, 2015
High Fiber Diets Reduce Risk of Diabetes
Posted June 04, 2015
Skin Bacteria a Cause of Diabetes?
Posted June 12, 2015
Efficacy and Safety of an SGLT-2 Inhibitor with Insulin for Type 2s
Posted May 28, 2015
Blood Biomarkers May Predict Risk of Severe Hypoglycemia
Posted June 12, 2015
Lilly Insulin: A Better Alternative than Lantus?
Posted June 19, 2015
Tight Blood Glucose Control and Cardiovascular Disease
Posted June 12, 2015
Are Postprandial Levels in T1 Patients Impacted by More Than Carbohydrates?
Posted May 28, 2015


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Have you recommended the use of an SGLT-2 inhibitor to any of your type 1 patients?

CME/CE of the Week
William Tamborlane, MD, FAAP, FACE

Category: General Diabetes
Credits:
 .75